Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although poor adherence to hormonal therapies such as aromatase inhibitors (AIs) is widely documented, to the authors' knowledge less is known regarding whether health beliefs predict treatment nonadherence. The objective of the current study was to evaluate the relationship between health beliefs (perceived susceptibility to breast cancer, perceived benefits of AI treatment, and perceived barriers to AI treatment) and adherence to AIs. METHODS: Postmenopausal women with early‐stage, estrogen receptor‐positive breast cancer who were currently receiving treatment with an AI completed the 3‐factor Health Beliefs and Medication Adherence in Breast Cancer scale and questionnaires concerning their demographics and symptoms. Adherence data (treatment gaps and premature discontinuation) were abstracted from participants' medical charts. Logistic regression analyses were conducted to evaluate the relationship between health beliefs and adherence. RESULTS: Among 437 participants, 93 (21.3%) were nonadherent. Those who perceived greater barriers to their AI treatment were more likely to demonstrate AI nonadherence behaviors by the end of their treatment period compared with those who reported fewer barriers to AI therapy (adjusted odds ratio, 1.71; 95% confidence interval, 1.03‐2.86 [P = .04]). In contrast, perceived susceptibility to cancer recurrence and perceived benefits of AIs did not appear to predict AI adherence. Minority individuals were found to have lower perceived susceptibility to breast cancer recurrence and higher perceived barriers to AI treatment (P<.05 for both). Conclusions: Greater perceived barriers appeared to predict nonadherence to AIs. Interventions addressing women's negative beliefs regarding the challenges of AI treatment are needed to help optimize adherence in survivors of breast cancer. Cancer 2017;169–176. © 2016 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GPOWER: A general power analysis program
Erdfelder, E., Faul, F., & Buchner, A. (1996) · Behavior Research Methods, Instruments, & Computers · doi:10.3758/bf03203630 · Cited by 4,864
Waddell, G., Newton, M., Henderson, I., Somerville, D., & Main, C. J. (1993) · Pain · doi:10.1016/0304-3959(93)90127-b · Cited by 3,167
Outline of a fear-avoidance model of exaggerated pain perception--I.
Lethem, J., Slade, P. D., Troup, J. D. G., & Bentley, G. (1983) · Behaviour Research and Therapy · doi:10.1016/0005-7967(83)90009-8 · Cited by 1,327
Hershman, D. L., Shao, T., Kushi, L. H., Buono, D., Tsai, W. Y., Fehrenbacher, L., Kwan, M., Gomez, S. L., & Neugut, A. I. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1132-4 · Cited by 870 · cited 1×
“DISCUSSION To achieve optimal clinical outcomes for survivors of breast cancer, adherence to AI therapy is essential.(17) In the current prospective cohort study, we found that participants who perceived greater barriers to AI treatment, as measured by the HBMABC, were more likely to later take breaks from their AI or…”
Murphy, C. C., Bartholomew, L. K., Carpentier, M. Y., Bluethmann, S. M., & Vernon, S. W. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2114-5 · Cited by 708 · cited 3×
“The nonadherence rate of 30% was selected based on rates observed in the literature.(3)”
InfluentialArmstrong, M. J., Mottershead, T. A., Ronksley, P. E., Sigal, R. J., Campbell, T. S., & Hemmelgarn, B. R. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2011.00892.x · Cited by 586
Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors
Irwin, M. L., Cartmel, B., Gross, C. P., Ercolano, E., Li, F., Yao, X., Fiellin, M., Capozza, S., Rothbard, M., Zhou, Y., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1547 · Cited by 324
Bender, C. M., Gentry, A. L., Brufsky, A. M., Casillo, F. E., Cohen, S. M., Dailey, M. M., Donovan, H. S., Dunbar-Jacob, J., Jankowitz, R. C., Rosenzweig, M. Q., et al. (2014) · Oncology Nursing Forum · doi:10.1188/14.onf.274-285 · Cited by 131
Sheppard, V. B., Faul, L. A., Luta, G., Clapp, J. D., Yung, R. L., Wang, J. H.-Y., Kimmick, G., Isaacs, C., Tallarico, M., Barry, W. T., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.7367 · Cited by 91 · cited 1×
“Although nonwhite individuals are no more likely to discontinue AI treatment than white individuals, previous work has shown that nonwhite individuals are less likely to initiate AI treatment.(25,26) Several factors have been examined to explain these differences, including lower rates of insurance coverage and a high…”
Cited by
Mao, J. J., Ismaila, N., Bao, T., Barton, D., Ben-Arye, E., Garland, E. L., Greenlee, H., Leblanc, T., Lee, R. T., Lopez, A. M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01357 · Cited by 359
Self-citationGraetz, I., McKillop, C. N., Stepanski, E., Vidal, G. A., Anderson, J. N., & Schwartzberg, L. S. (2018) · Journal of Cancer Survivorship · doi:10.1007/s11764-018-0682-z · Cited by 106
Toivonen, K., Williamson, T., Carlson, L., Walker, L., & Campbell, T. (2020) · Cancers · doi:10.3390/cancers13010107 · Cited by 77
Finitsis, D. J., Vose, B. A., Mahalak, J. G., & Salner, A. L. (2019) · Psycho-Oncology · doi:10.1002/pon.4959 · Cited by 68
Metadata
- Authors
- Brier, M. J., Chambless, D. L., Gross, R., Chen, J., & Mao, J. J.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2016-08-29
- Volume
- 123
- Issue
- 1
- Pages
- 169-176
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2514436481
- Cited by
- 49
- References
- 9
- FWCI
- 5.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.